Top-Searched Lab Tests
Explore Conditions
Explore Biomarkers
Explore Diagnostic Labs
New Lab Tests
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| PD-L1 22C3 FDA for NSCLC | Immunoassay | Tissue | 1-2 d | NeoGenomics |
| PD-L1 22C3 FDA (KEYTRUDA®) for Cervical | Immunoassay | Tissue | 1-2 d | NeoGenomics |
| PD-L1 22C3 FDA (KEYTRUDA®) for HNSCC (Head & Neck) | Immunoassay | Tissue | 1-2 d | NeoGenomics |
| PD-L1 28-8 (OPDIVO®) for Gastric/GEJ/EAC | Immunoassay | Tissue | 1-2 d | NeoGenomics |
| PD-L1 22C3 FDA (KEYTRUDA®) for TNBC (Breast) | Immunoassay | Tissue | 1-2 d | NeoGenomics |
PD-L1 22C3 FDA for NSCLC
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
PD-L1 22C3 FDA (KEYTRUDA®) for Cervical
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
PD-L1 22C3 FDA (KEYTRUDA®) for HNSCC (Head & Neck)
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
PD-L1 28-8 (OPDIVO®) for Gastric/GEJ/EAC
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
PD-L1 22C3 FDA (KEYTRUDA®) for TNBC (Breast)
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
Featured Companion Diagnostics
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| xT CDx | NGS | Tissue, Whole Blood, Saliva | 10-14 d | Tempus AI |
| Vysis Chronic Lymphocytic Leukemia (CLL) Panel | Chromosomal / Cytogenetics | Whole Blood, Bone Marrow | 5 d | MPLN |
| PD-L1 SP263 FDA for NSCLC | Immunoassay | Tissue | 1-2 d | NeoGenomics |
| PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) | Chromosomal / Cytogenetics | Tumor Tissue | — | ARUP Laboratories |
| nAbCyte™ Anti‑AAVRh74var HB‑FE Assay (nAbCyte Assay) | Other | Serum | 7-10 d | Labcorp |
xT CDx
Methodology:NGS
Specimen:Tissue, Whole Blood, Saliva
TAT:10-14 d
Lab:Tempus AI
Vysis Chronic Lymphocytic Leukemia (CLL) Panel
Methodology:Chromosomal / Cytogenetics
Specimen:Whole Blood, Bone Marrow
TAT:5 d
Lab:MPLN
PD-L1 SP263 FDA for NSCLC
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Methodology:Chromosomal / Cytogenetics
Specimen:Tumor Tissue
TAT:—
Lab:ARUP Laboratories
nAbCyte™ Anti‑AAVRh74var HB‑FE Assay (nAbCyte Assay)
Methodology:Other
Specimen:Serum
TAT:7-10 d
Lab:Labcorp
Featured Sponsored Testing
| Program Name | Therapeutic Area(s) | Condition | Lab |
|---|---|---|---|
| Comprehensive DMD testing | Musculoskeletal | Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) | Revvity Omics, Inc. |
| Invitae Inborn Errors of Immunity and Cytopenias Panel | Immunology | Severe Combined Immunodeficiency (SCID), Combined Immunodeficiency (CID) | Invitae | Labcorp |
| NovoDETECT Primary Hyperoxaluria Panel | Nephrology | Primary Hyperoxaluria (PH) | Blueprint Genetics |
| Renasight™ Genetic Kidney Panel | Nephrology | Chronic Kidney Disease (CKD), APOL1-Mediated Kidney Disease (AMKD) | Natera |
| Color Hereditary Cancer Test | Oncology | Ovarian Cancer, Uterine/Endometrial Cancer | Color Health |
Comprehensive DMD testing
Therapeutic Area(s):Musculoskeletal
Condition:Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD)
Lab:Revvity Omics, Inc.
Invitae Inborn Errors of Immunity and Cytopenias Panel
Therapeutic Area(s):Immunology
Condition:Severe Combined Immunodeficiency (SCID), Combined Immunodeficiency (CID)
Lab:Invitae | Labcorp
NovoDETECT Primary Hyperoxaluria Panel
Therapeutic Area(s):Nephrology
Condition:Primary Hyperoxaluria (PH)
Lab:Blueprint Genetics
Renasight™ Genetic Kidney Panel
Therapeutic Area(s):Nephrology
Condition:Chronic Kidney Disease (CKD), APOL1-Mediated Kidney Disease (AMKD)
Lab:Natera
Color Hereditary Cancer Test
Therapeutic Area(s):Oncology
Condition:Ovarian Cancer, Uterine/Endometrial Cancer
Lab:Color Health